ProFactor Pharma

Transforming treatment of haemophilia

ProFactor Pharma Ltd (PFP) is developing factor VIII (FVIII) for the treatment of Haemophilia.  Our business is to manufacture low cost recombinant FVIII to a severely undersupplied world market.

According to the World Health Organisation (WHO) almost three quarters of the haemophilia patient population receive inadequate or no treatment at all.

Recent News

Press Release March 2015 – Penrose enquiry

Hope for Haemophiliacs Despite the controversy and disappointment emerging from the final report of the Penrose Inquiry into contaminated blood, which led to infection and death of hundreds of Scots, including haemophiliacs, new hope is emerging in a small laboratory...

read more

Series A Financing

ProFactor Pharma closed its Series A round of financing in August 2013. The funding was provided principally by members of the Business Angel Syndicate Kelvin Capital, Glasgow, and the Scottish Investment Bank Co-investment Fund. Some of the existing shareholders,...

read more